APRIA®

RESPIRATORY CARE

COPD Care Follow-up Program

Using the CAT Assessment to Support COPD Care Decisions

Because COPD is a progressive disease, it is vital to understand the patient's current risk level during their progression, so that healthcare prescribers can make important treatment decisions. The COPD Assessment Test™ (CAT) and GOLD risk group identification can be useful tools for the prescriber.

To support prescribers caring for COPD patients, Apria may conduct these COPD risk assessments according to GOLD guidelines on an ongoing basis for patients receiving oxygen and other bilevel therapy.

GOLD ABE Assessment Tool



©2022, 2023 Global Initiative for Chronic Obstructive Lung Disease, Inc.

A Comprehensive COPD Care Program Designed for You and Your Patients

ROUTINE FOLLOW-UP

- In-person, phone, and telehealth patient follow-up
- GOLD Risk Group Identification

PRESCRIBER COLLABORATION

- Patient risk assessment reviews with prescribers
- Consultations on therapeutic options based on patient status

TREATMENT AND MONITORING OPTIONS

- Oxygen & Nebulizer Therapy
- Respiratory Medications
- Overnight Oximetry
- Bilevel & Non-Invasive Ventilation

Your Apria Representative: [First Name Last Name]

Phone: [555.555.5555] Fax: [555.555.5555]

©2026 Apria Healthcare Group LLC | RES-4601 March 2026

An **Accendra Health** Brand